.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
QuintilesIMS
Fuji
Mallinckrodt
Deloitte
Baxter
Moodys
Chubb
Harvard Business School
Merck

Generated: September 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Antiarrhythmic method utilizing fluoroalkoxy-N-piperidyl and pyridyl benzamides
Abstract:Certain compounds in which a carbon atom of a pyrrolidine or piperidine ring is bonded directly or through a methylene group to the nitrogen of a substituted benzamido group, and their pharmaceutically acceptable salts, are found to be active as antiarrhythmic agents.
Inventor(s): Banitt; Elden H. (Woodbury, MN), Bronn; William R. (St. Paul, MN)
Assignee: Riker Laboratories, Inc. (Northridge, CA)
Application Number:05/580,891
Patent Claims: 1. A method for the treating and prevention of arrhythmias in a mammal in need thereof comprising administering an effective dose less than the toxic amount of the compound of the formula: ##STR34## wherein R.sub.f is a perfluoroalkyl radical containing from one to three carbon atoms, n is one to three, p is one or two, Q is a carbon-nitrogen bond, methylene or methylmethylene and R and R' are hydrogen, methyl or ethyl, or a pharmaceutically acceptable salt thereof, to said mammal.

2. The process of claim 1 wherein the route of administration is oral.

3. A method according to claim 1 wherein p is 2.

4. A method according to claim 1 wherein R.sub.f is trifluoromethyl, n is two and the substituents are in the 2,5positions.

5. A method for the treating and prevention of arrhythmias in a mammal in need thereof comprising administering an effective dose less than the toxic amount of a compound of the formula: ##STR35## wherein R.sub.f is a perfluoroalkyl radical containing from one to three carbon atoms, n is one to three, p is one or two, Q is methylene or methylmethylene and R and R'are hydrogen, methyl or ethyl, or a pharmaceutically acceptable salt thereof to said mammal.

6. A method according to claim 5 wherein R.sub.f is trifluoromethyl, n is two and the substituents are in the 2,5 positions.

7. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-methyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof.

8. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(3-piperidyl)-benzamide or a pharmaceutically acceptable salt thereof.

9. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-ethyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof.

10. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-ethyl-2-pyrrolidyl)methyl]benzamide, or a pharmaceutically acceptable salt thereof.

11. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-]1-(2-piperidyl)-ethyl]benzamide or a pharmaceutically acceptable salt thereof.

12. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(6-methyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof.

13. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(6-methyl-2-piperidyl)methyl]benzamide hydrochloride.

14. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide or a pharmaceutically acceptable salt thereof.

15. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide hydrochloride
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Daiichi Sankyo
Johnson and Johnson
Citi
UBS
Medtronic
Argus Health
Federal Trade Commission
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot